VIGL Vigil Neuroscience, Inc. EV/EBITDA Multiple
Vigil Neuroscience (VIGL) implements ESG and bioethics principles in the development of drugs for orphan brain pathologies. The business model relies on the global expansion potential of unique, high-yield medications. This price chart demonstrates the EV/EBITDA ratio, which currently stands at . Meanwhile, the company's operational processes are strictly limited by FDA medical standards, including regulations on biohazardous waste processing.
vigilneuro.com - analytical breakdowns and key metrics (VIGL)
- current price and projected stock value:
- market capitalization data:
- issuer book value statistics:
- company liabilities and liquidity data:
Debt to Equity Vigil Neuroscience|VIGL - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Vigil Neuroscience, Inc.|VIGL - Company Cumulative Debt|Debt to Book Value Vigil Neuroscience, Inc.|VIGL - Company Long-Term Debts|Company Short-Term Debt Vigil Neuroscience|Quick Liquidity vigilneuro.com
- business earnings and investment ratios data:
VIGL - Company Net Income|Expected Profit Vigil Neuroscience|VIGL - Business Payback Period|Forward P/E Multiple Vigil Neuroscience, Inc.|VIGL - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Vigil Neuroscience, Inc.|VIGL - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Vigil Neuroscience|VIGL - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months vigilneuro.com|VIGL - Earnings per share growth this year|Earnings growth forecast for next year Vigil Neuroscience
Initial company analysis:Vigil Neuro (VIGL)
Investors must filter out market noise when assessing the debt load of Vigil Neuroscience (VIGL) during a period of volatile interest rates. The implementation of AI and robotic platforms for compound design optimizes operating expenses, thereby enhancing business resilience. By analyzing the historical EV/EBITDA trend of Vigil Neuroscience (VIGL), one can evaluate the ratio of total enterprise value to operating profit, where a decline in the metric indicates either an undervalued asset or a risk of margin compression.
Competitors of Vigil Neuroscience
EV/EBITDA Multiple BIIB (Biogen Corp)|Enterprise Value to EBITDA Multiple Neurocrine Corp|Regencell Bioscience - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio axsome.com AXSM|ACADIA Pharmaceuticals Inc. (ACAD) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|XENE (Xenon Pharmaceuticals Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio VKTX|SUPN: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Catalyst Pharmaceuticals (CPRX)|denalitherapeutics.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple HRMY (Harmony Biosciences Holdings, Inc.)|Biohaven Ltd (BHVN) - Company Value to EBITDA|AMLX: Enterprise Value to EBITDA Ratio|TRVI - EV/EBITDA Multiple|Praxis Precision Medicines (PRAX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|anavex.com - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CeriBell|Company Value to EBITDA Prothena Corporation PLC PRTA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alector, Inc. (ALEC)|Total Company Value to Operating Income Before Depreciation Ratio Annexon Biosciences Inc.|EV/EBITDA Multiple OMER (Omeros)|NGNE - Enterprise Value to EBITDA Ratio|AC Immune SA - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Voyager Therapeutics Inc VYGR|NMRA: EV/EBITDA Multiple|Company Value to EBITDA Scilex Holding Company, Inc. (SCLX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tevogen Bio Holdings|Enterprise Value to Operating Income Before Depreciation ACOG (Alpha Cognition Corp)|EV/EBITDA Multiple CGTX|Enterprise Value to EBITDA Ratio Inhibikase Therapeutics Inc IKT|EV/EBITDA Multiple SAVA (Cassava)|Assertio Holdings (ASRT) - Company Value to EBITDA|COYA: Enterprise Value to EBITDA Ratio|VTGN: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|OVID: EV/EBITDA Multiple|ABOS - Total Company Value to Operating Income Before Depreciation Ratio|CRVO (CervoMed Inc) - EV/EBITDA Multiple|ATHE - Enterprise Value to EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Clene Inc. (CLNN)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PEPG (pepgen.com)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jupiter Neurosciences JUNS|RLMD: Enterprise Value to Operating Income Before Depreciation|Annovis Bio Corp - EV/EBITDA Multiple|Company Value to EBITDA Grace Therapeutics, Inc.|AIFF (Firefly Neuroscience, Inc) - Enterprise Value to EBITDA Ratio|Klotho Neurosciences (KLTO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeuroSense Therapeutics Ltd|RVPH: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MetaVia Inc (MTVA)|NRXS - Company Value to EBITDA|Helius Medical Technologies - Enterprise Value to EBITDA Ratio|Passage Bio Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Neuphoria - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Minerva Neurosciences Inc NERV|ATHA: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Addex ADXN|ALZN (Alzamend Neuro Inc.) - EV/EBITDA Multiple|Cyclerion (CYCN) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protagenic Therapeutics (PTIX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization KTTA (pasitheaclinics.com)|Cortigent - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ATXI|BCLI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CARA (caratherapeutics.com) - Enterprise Value to Operating Income Before Depreciation|CHRO: EV/EBITDA Multiple|Company Value to EBITDA Eliem Therapeutics Inc. (ELYM)|Enterprise Value to EBITDA Ratio ITCI|EV/EBITDA Multiple Longboard|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Marinus Pharmaceuticals (MRNS)|NKGN (nkgenbiotech.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeuroBo Pharmaceuticals, Inc. NRBO|Sage Therapeutics Inc. (SAGE) - Company Value to EBITDA|SNPX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Trevena Inc TRVN|WENA: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio cerevel.com
